TG Therapeutics, Inc.

TGTX

US88322Q1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-07 EDT			5-day change	1st Jan Change
15.85 ^USD	+0.25%		-2.76%	-7.20%

05-01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
05-01	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

TG Therapeutics Mourns the Loss of Board Member, William J. Kennedy

June 29, 2021 at 07:30 am

TG Therapeutics, Inc. announced with great sadness the passing of longtime Board Member, William J. Kennedy, PhD.

Latest news about TG Therapeutics, Inc.

Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	05-01	MT
Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M	05-01	MT
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
North American Morning Briefing : Investors Brace -2-	04-29	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	04-18	MT
Sector Update: Health Care	04-18	MT
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	04-18	MT
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	04-18	CI
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	03-13	MT
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	03-01	MT
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	02-29	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	02-28	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	02-28	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	02-28	MT
Transcript : TG Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	02-28	MT
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28	CI
TG Therapeutics to Receive $12.5 Million Milestone Payment for Launch of Briumvi in Europe	02-26	MT
Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.	02-11	CI
B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating	02-05	MT
HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating	01-11	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	01-10	MT
TG Therapeutics Shares Fall After Reporting Net Product Preliminary Revenues for Briumvi; Provides 2024 Targets	01-10	MT

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Sector

Biotechnology & Medical Research

Calendar

2024-06-11 - Goldman Sachs Global Healthcare Conference - Fireside Chat

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for TG Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.85 USD

Average target price

31.5 USD

Spread / Average Target

+98.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TG THERAPEUTICS, INC.	-7.20%	2.27B
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research

TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Biotechnology & Medical Research

TG Therapeutics Mourns the Loss of Board Member, William J. Kennedy

Latest news about TG Therapeutics, Inc.

Chart TG Therapeutics, Inc.

Company Profile

Income Statement Evolution

Ratings for TG Therapeutics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research